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ABSTRACT
Multimodal nanoparticles are nanoparticles containing contrast agents for PAT and one or more ofluminescence imaging, x-ray imaging, and/or MRI. The multimodal nanoparticles can have a dielectric core comprising an oxide with a
metal coating on the core. The particles can be metal speckled. The multimodal nanoparticles can be used for therapeutic
purposes such as ablation of tumors or by neutron capture in
addition to use as contrast agents for imaging.
6 Claims, 13 Drawing Sheets
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MULTIMODAL NANOPARTICLES FOR
NON-INVASIVE BIO-IMAGING

oxide, for example silicon dioxide, with a metal, for example
gold, deposited on the dielectric core. The multimodal nanoparticle also has a plurality of at least one moiety that exhibits
luminescence, magnetic or paramagnetic properties, x-ray
opacity, or any combination of these properties. A single
moiety can act as one or more contrast agents for photo
acoustic tomography (PAT) imaging, luminescence imaging,
magnetic resonance (MR) imaging, and x-ray imaging. The
multimodal nanoparticle can have multiple moieties which
behave as different contrast agents for different imaging techniques. For example, in one embodiment a luminescence
imaging moiety can be a dye, a quantum dot, a phosphor or a
combination thereof. In another embodiment an MR imaging
moiety can be at least one chelated lanthanide or transition
metal.
In one embodiment of the invention the multimodal nanoparticle is a metal speckled particle, for example gold speckled silicate (GSS) nanoparticle. The metal deposition is
speckled where a discontinuous metal and dielectric core
have a non-discrete interface with an interpenetrated gradient. In an embodiment of the invention, the multimodal nanoparticles can also have a biomolecule or a surface functional
group attached to its surface by any means such that the
biomolecule or functional group allow specific targeting of a
tumor cell.
Another embodiment of the invention is directed to a
method for multimodal bio-imaging where a multimodal
nanoparticle, as described above, is introduced to a desired
location, which is then imaged by photo acoustic tomography
(PAT) and at least one other imaging method selected from
magnetic resonance, luminescence, and x-rays imaging. The
multimodal nanoparticles enhance the contrast observed in
the resulting images. The different modes of imaging can be
simultaneously or sequentially performed.
Another embodiment of the invention is directed to a
method for using multimodal nanoparticles, as described
above, for therapeutic purposes where a multimodal nanoparticle is delivered to a desired target region, such as tissue
containing tumors. The multimodal nanoparticle can then be
irradiated with electromagnetic radiation which generates
heat when the multimodal nanoparticles absorb radiation.
Sufficient electromagnetic radiation can be provided to cause
local heating that is sufficiently high to kill tumor cells that
have the multimodal nanoparticles on or contained within the
tumor. Electromagnetic radiation can be from any region of
the spectrum including, but not limited to infrared, near infrared, visible, near ultraviolet and ultraviolet. In another
embodiment of the invention, irradiation of the multimodal
nanoparticles for therapeutic purposes can be neutron irradiation, such that the multimodal nanoparticles emit x-rays,
gamma rays or Auger electrons, which destroy cells in the
vicinity of the multipurpose nanoparticles.
Another embodiment of the invention is a method for preparing multimodal nanoparticles as described above by forming a core of primarily a dielectric material, depositing a
metal on the core, and attaching at least one moiety that
exhibits luminescence, magnetic or paramagnetic properties,
x-ray opacity, to the core or the metal. The core can be formed
by condensation of a metal oxide precursor in a water-in-oil
microemulsion. The metal can be deposited by reduction of a
dissolved metal salt in the presence of a reducing agent. One
moiety that can be attached to the nanoparticle is a chelated
lanthanide or transition metal where a ligand bound alkoxysilane chelated to a metal is condensed with the metal oxide
precursor during formation of the core or by condensation of
the alkoxysilane with a residue from the precursor after formation of the core. Some moieties, such as luminescence

CROSS-REFERENCE TO RELATED
APPLICATION
This application is the U.S. national stage application of
International Patent Application No. PCT/US2008/074630,
filed Aug. 28, 2008, which claims the benefit of U.S. Provisional Patent Application No. 60/968,476, filed Aug. 28,
2007, the disclosures of which are hereby incorporated by
reference in their entireties, including all figures, tables or
drawings.
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BACKGROUND OF THE INVENTION

15

Bio-imaging techniques can non-invasively measure biological functions, evaluate cellular and molecular events, and
reveal the inner workings of a body. Examples ofbio-imaging
techniques include magnetic resonance imaging (MRI),
positron emission tomography (PET), x-ray tomography,
luminescence (optical imaging), and ultrasound. Each of
these techniques can differ from one another in the resolution,
sensitivity, and anatomical information they provide about
the subject. For example, though optical imaging has high
sensitivity, it provides limited anatomical background information, and can display artifacts due to tissue absorbance and
scattering. Photo acoustic tomography (PAT), an emerging
non-invasive imaging modality, uses a non-ionizing optical
(pulsed laser) source to generate contrast, which is detected as
an acoustic signal whose scattering is 2-3 orders of magnitude
weaker than optical scattering in biological tissues, the primary limitation of optical imaging. MRI on the other hand
can be used to generate contrast to detect tumors in deep
tissue and provide true three dimensional imaging ofbiological structures and processes at cellular resolution. X-ray contrast is useful to differentiate tissues with small differences in
their opacity.
It is often necessary to use more than one imaging technique to integrate the strengths of each while overcoming the
limitations of the individual techniques to improve diagnostics, preclinical research and therapeutic monitoring. However, each of these techniques typically uses a different contrast agent, so using more than one bio-imaging technique
requires additional time, expense and can complicate the
diagnostic process. It would be desirable to have a multimodal contrast agent that can be used for more than one bioimaging technique. Multi-modal contrast agents for bioimaging can also serve as important tools for developing and
benchmarking experimental imaging technologies by using
parallel experiments with mature, proven technologies. The
application of multimodal contrast agents is particularly
important for developing less expensive, more available, and
reliable bio-imaging technologies, such as PAT, that have the
potential to make advanced medical diagnostics available to
impoverished populations, as well as more commonplace
worldwide. Although imaging technologies such as CT and
MRI have become prevalent, the related capital costs associated with obtaining and maintaining existing equipment
financially limits its widespread application, even in modern
societies.

20

25

30

35

40

45

50

55

60

BRIEF SUMMARY OF THE INVENTION
In an embodiments of the invention, a multimodal nanoparticle, for use as a contrast agent for PAT and at least one
other imaging method, has a dielectric core of at least one
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providing dyes or phosphors or quantum dots, can be admixing with the metal oxide precursors and be bound or
entrapped within the core upon condensation.

with TR=500 ms; and Panel IV is the T 2 weighted spin-echo
image with TR=500 ms, TE= 100 ms according to an embodiment of the invention.
FIGS. lSA-B show representative (FIG. lSA) SEM and
(FIG. lSB) TEM images of multimodal nanoparticles according to the invention.
FIG. 16 shows x-ray contrast from the multimodal nanoparticles (A and B) showing strong contrast to that of water
(C) according to an embodiment of the invention.
FIGS. 17A-D show in-vivo MR images of multimodal
nanoparticle labeled 174 cells in mouse leg where: FIG. 17A
is spin echo (Msme) TR=l s, TE=30 ms, matrix=256x256,
FOV=2.8x2.74 cm, 2 avg, 1 mm slice; FIG. 17B gradient
echo (FLASH) TR=500 ms, TE=4 ms, matrix=256x256,
FOV=2.8x2.74 cm, 2 avg, 1 mm slice; FIG. 17C spin echo
(Msme) TR=276 ms, TE=5.5 ms, matrix=128x256,
FOV=2.8x2.74 cm, 2 avg, 1 mm slice; and FIG. 17D spin
echo (Msme) fat suppression, TR=276 ms, TE=5.5 ms,
matrix=128x256, FOV=2.8x2.74 cm, 2 avg, 1 mm slice,
according to an embodiment of the invention.
FIG. 18 shows PAT images of a mouse before (left) and
after (right) the injection with the multimodal nanoparticles
where the red (appearing as a plurality of dark regions within
a white region of the image) shows the contrast in the presence of the multimodal nanoparticles according to an
embodiment of the invention.
FIGS. 19A-B show a PAT image (FIG. 19A) of an animal
model of a tumor region 3 hours post injection with multimodal nanoparticles after subtracting the initial image, and an ex
vivo fluorescence image (FIG. 19B) of the tumor section
according to an embodiment of the invention.
FIG. 20 is a plot of temperature rise in a solution containing
10 mg/mL GSS multimodal nanoparticles on exposure to
continuous illumination from a 785 nm laser with a 350 mA
output according to an embodiment of the invention.
FIGS. 21A-D show an A549 cell with GSS multimodal
nanoparticles before laser exposure (FIG. 2 lA) and after laser
exposure (FIG. 21B) for 100 s, which formed a bubble due to
the heating and anA54 9 cell before laser exposure (FIG. 21 C)
and after laser exposure (FIG. 21D) for 100 s without bubble
formation according to an embodiment of the invention.
FIGS. 22A-B show cells labeled with GSS multimodal
nanoparticles along a path of laser illumination (FIG. 22A)
and at a higher magnification (FIG. 22B) according to an
embodiment of the invention.
FIG. 23 shows a photograph of a histological section of a
tumor after thermal ablation with GSS multimodal nanoparticles illuminated with 785 nm laser for 5 minutes according
to an embodiment of the invention.
FIG. 24 shows an Hand Estain of a tumor section indicating destruction of tumor cells upon illumination ofGSS multimodal nanoparticles according to an embodiment of the
invention.

BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 schematically depicts a multimodal nanoparticle
according to an embodiment of the invention.
FIG. 2 shows a schematic of passive targeting of tumor
cells by multimodal nanoparticles promoted by enhanced
permeability and retention according to an embodiment of the
invention.
FIG. 3 shows a photo acoustic tomography PAT image of
gold speckled silica nanoparticles (GSS) and for a silica particle according to an embodiment of the invention.
FIG. 4A shows a T 1 weighted magnetic resonance (MR)
image of a silica particle and that of a Gd-doped GSS sample
and FIG. 4B shows a T 2 weighted T 1 weighted magnetic
resonance (MR) image of a silica particle and that of a GSS
sample Where The GSS particle imparts a positive enhancement in the T 1 weighted image and a negative enhancement
for a T 2 weighted image according to an embodiment of the
invention.
FIGS. SA-B show transmission electron microscopic
(TEM) images of Gd-doped GSS multimodal nanoparticles
of about 100 nm (FIG. SA) and about 50 nm (FIG. SB)
according to an embodiment of the invention.
FIG. 6 shows a TEM image of Gd-doped GSS multimodal
nanoparticles of about 225 nm according to an embodiment
of the invention;
FIG. 7A shows a high resolution TEM image where dark
gold speckles are observed on the silica of a GSS multimodal
nanoparticle and FIG. 7B shows a dark field TEM image of
the GSS multimodal nanoparticle according to an embodiment of the invention.
FIG. 8 shows a high resolution TEM image where the
lattice planes of the gold speckles deposited on silica ofa GSS
multimodal nanoparticle according to an embodiment of the
invention.
FIG. 9 shows an EDS spectrum of Gd-doped GSS multimodal nanoparticles showing the presence of Si, 0, Au and
Gd according to an embodiment of the invention.
FIG. lOA shows A) T 1 -weighted (repetition time (TR)=l 1
000 ms, echo time (TE)=4.2 ms), and FIG. lOB shows
T 2 *TR=500 ms, TE=40 ms images of serial dilutions of Gd
doped GSS nanoparticle (a) 0.24, (b) 0.12, (c) 0.06, (d) 0.03
and (e) 0.015 mM of Gd in 0.5% agarose and (f) 0.5% agarose
(as control) according to an embodiment of the invention.
FIGS. llA-C show linear plots of Gd concentration vs.
(FIG. llA) 1/T 1 , (FIG. llB) 1/T2 , and (FIG. llC) 1/T2 * to
determine ionic relaxivities R 1 , R 2 , and R2 * for Gd-doped
GSS multimodal nanoparticles according to an embodiment
of the invention.
FIG. 12 shows PAT contrast for gold and GSS multimodal
nanoparticles of similar size and concentration (8 µL of 10
mg/mL) in a tissue-like phantom with background absorption
coefficient µa=0.007 mm- 1 and reduced scattering coefficient
µa'=0.5 mm- 1 according to an embodiment of the invention.
FIGS. 13A-B show a PAT (FIG. 13A) and MRI T 1 (FIG.
13B) contrast from the same phantom using 1, 3 and 5 µL
(particle concentration 10 mg/mL) of Gd-doped GSS multimodal nanoparticles with background coefficient µa=0.007
mm- 1 according to an embodiment of the invention.
FIG. 14 Panel I shows the position of J 774 microphage
cells labeled with GSS multimodal nanoparticles marked as A
and unlabeled cells marked as B in a phantom; Panel II shows
the PAT image; Panel III is a T 1 -weighted spin-echo image
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DETAILED DESCRIPTION OF THE INVENTION
According to various embodiments, multimodal nanoparticles have a plurality of agents chosen from fluorescent contrasting agents, MRI contrasting agents, an x-ray contrasting
agents, and PAT contrasting agents.A single moiety can function as one on a plurality of contrast agents. Examples of
contrast agents for luminescence (such as fluorescence, phosphorescence, and colorimetric) imaging include, but are not
limited to, dyes, quantum dots, and phosphors. Examples of
MRI imaging contrast agents include, but are not limited to,
paramagnetic substances or substances containing particles
exhibiting ferromagnetic, ferromagnetic or super paramag-

US 8,361,437 B2
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netic behavior. Paramagnetic MRI contrast agents can be, for
example, transition metal chelates and lanthanide chelates
like Mn-EDTA (ethylene diamine tetraacetic acid) and GdDTPA (diethylene triamine pentaacetic acid).
IR absorbing dyes include indocyanine green, Cy-5 and
others. Contrast agents for PAT work by selectively absorbing
radiation in certain organs, or parts of organs, and efficiently
converting that radiation into pressure waves or by scattering
and diffusing the incipient light so that it more uniformly
illuminates the target organs. The radiation may be electromagnetic radiation in the visible, infrared, microwave or
other parts of the electromagnetic spectrum. Contrast agents
for PAT include, but are not limited to, dyes, metal nanoparticles, and metal nanoshells, and metal speckled nanoparticles. Nanoshells can be composed of a dielectric core, usually silica, surrounded by a discrete thin continuous metal
shell, typically gold. Metal speckled nanoparticles can be
composed of a dielectric core, usually silica, surrounded by
an interpenetrated, molecularly-seeded, discontinuous gold
film. Metal speckled nanoparticles have a non-discrete interface with the dielectric core establishing an interpenetrated
gradient between the core and the outer discontinuous metallic film. These features result in alternative physical parameters that can be adjusted and modified to optimize particle
performance for imaging and therapeutic applications.
In one embodiment of the invention, multimodal nanoparticle can include a core formed of a dielectric material such as
Si0 2 . The core can include fluorescent dyes which can cover
a desired spectrum range from visible to near IR. In other
embodiments of the invention, the core can contain quantum
dots and/or phosphors.
In one of the embodiments, multimodal nanoparticle can
be doped with a (para) magnetic element, such as lanthanides,
including Gd, Eu, Dy, and Tb, and/or transition metals including Mn, Fe etc. These paramagnetic species, in addition to
their magnetic influence and ability to generate contrast for
MRI, can have a luminescence property. In certain embodiments, these lanthanides function as fluorescent agent in the
multimodal nanoparticle in addition to their function as the
MRI contrast agent. The heavy atomic weight lanthanides
and/or transition elements can function as an X-ray contrast
agent in the multimodal nanoparticles.
In one embodiment of the invention, the multimodal nanoparticle contain fluorescent species included on a silica core a
paramagnetic element tethered to the particle and speckled
with a metallic element, such as gold, silver, copper, or zinc.
This interpenetrated, discontinuous metallic surface on the
primarily dielectric core imparts photo acoustic contrast from
the particle. The metallic element and a lanthanide/transition
paramagnetic element provide enhancement to the x-ray contrast. In one embodiment of the invention schematically
depicted in FIG. 1, the metallic coating results in a speckled
gold nanoparticle, with Gd paramagnetic species and Fluorescein isothiocyanate FITC dye within the silica core. One of
ordinary skill in the art will understand that FIG. 1 is exemplary and that other contrast agents, geometries and coatings
can be included.
In embodiments of the invention, the nanoparticles can be
from less than 50 nm to more than 350 nm in cross section. In
one embodiment of the invention the nanoparticles can be
from less than 50 nanometers to about 100 nm in cross section. Generally, but not necessarily, the nanoparticles will be
approximately spherical in shape; however, the shape can be
that of any ovoid, rod, plate or irregular.
In addition to the multimodal nanoparticles value as mu!tifunctional contrast agents, in embodiments of the invention,
the multimodal nanoparticles can be employed in therapeutic

application as traceable hyperthermia agents. The multimodal nanoparticles can be injected into an animal and actively/
passively targeted to a tumor site, exploiting the well known
enhanced permeability and retention (EPR) effect, as illustrated in FIG. 2. The GSS nanoparticles can absorb light in the
visible to Near Infrared (NIR) wavelength range where heat is
generated as a result of their absorption. The heat generating
ability makes them useful for therapeutic hyperthermia applications. The located tumors can be specifically targeted to
heat and destroy the malignant cells that include the multimodal nanoparticles.
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Materials Tetraethylorthosilicate (TEOS), Triton X-100
(TX-100 ),
n-hexanol,
3-(aminopropy l)triethoxysilane
(APTS), and cyclohexane were purchased from Aldrich
Chemical Co. Inc. N-(Tri-methoxysilyl-propyl)ethyldiaminetriacetic acid disodium salt (TSPETE) (45% wt % solution
in water) was purchased from Gelest Co., gold chloride,
gadolinium acetate, and hydrazine hydrate were obtained
from Acros Organics, and ammonium hydroxide (NH4 0H,
28-30 wt%) was obtained from the Fisher Scientific Co. All
other chemicals were of analytical reagent grade. Deionized
(DI) water (NANOpure, Barnstead) was used for the preparation of all solutions.
Synthesis of Gd-Doped GSS Nanoparticles. The complete
synthesis of the multimodal nanoparticles was done in one pot
using reverse micelles. The water-in-oil (W/O) microemulsion was prepared by mixing TX-100 cyclohexane, n-hexanol
(1:4.2:1 v/v), and appropriate water. n-Hexanol was used as a
co-surfactant to the nonionic surfactant, TX-100. An amount
of0.050 mL ofTEOS was added to the microemulsion and
allowed to equilibrate for 30 min. The hydrolysis and polymerization ofTEOS was initiated by adding 0.05-0.200 L of
NH4 0H. The overall W 0 (water to surfactant molar ratio) of
NH4 0H was 10 after addition. The silica polymerization
reaction ran for 24 hour, the surface of the silica nanoparticle
was modified with the addition of0.025 mL ofTSPETE and
0.050 mL ofTEOS. The resulting solution was stirred overnight. Subsequently, 0.10 mL of0.1 M Gd(III) acetate solution was added and stirring for 4 hours. This was followed by
addition of0.5 mL of0.25 M HAuCl4 , prepared in degassed
water, and 1.1 M solution of reducing agent (hydrazine
hydrate). The solution was stirred for about 12 hours. The
progress of the reaction at each step was monitored by UV-vis
absorption spectroscopy. The Gd-doped GSS nanoparticles
were isolated from the microemulsion by adding 5 mL of200
proof ethanol. The solution was stirred for a few minutes. This
led to the complete breakdown of reverse micelles with the
formation of two immiscible layers of aqueous ethanol and
cyclohexane. The nanoparticles along with the surfactant
molecules were accumulated in bottom ethanol layer. The top
layer of cyclohexane was carefully removed, and the particles
were centrifuged. The particles were washed three times with
ethanol and five times with water in order to completely
remove surfactant molecules. Each centrifugation step, during washing was followed by vortexing and sonication to
redisperse the pelleted particles. After complete removal of
surfactant the particles were redispersed in N anopure water to
obtain a concentration of about 2 mg/mL for further characterization.
Particle Size Measurements. The particle size and distribution were measured by dynamic light scattering (DLS)
using a Microtrac NANOTRAC and CPS disk centrifuge. The
size and morphology of the particles were determined by
transmission electron microscopy (TEM). TEM and energy-
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dispersive X-ray spectroscopy (EDS) spectra of the particles
were done using JEOL 2010F transmission electron microscope.
Inductively Coupled Plasma Experiments. Inductively
coupled plasma (ICP) measurements were performed using a
Perkin-Elmer Plasma 3200 system equipped with two monochromators covering the spectral range of 165-785 nm with a
grated ruling of3600 lines/mm. Briefly, 0.050 g of the nanoparticle sample was digested using aqua regia solution. [Caution: Aqua regia digestion should be performed with care in a
hood. Its reaction with GSS nanoparticles produces acrid and
toxic fumes.] Au and Gd completely dissolved in the aqua
regia, whereas the silica matrix settled at the bottom of the
container as a white powder. After complete digestion, the
solution was filtered to separate the silica particles as residue.
The particles were washed three times with aqua regia solution and twice with nanopure water. The filtrate and the particles were all collected together and boiled to concentrate the
volume to 15.0 mL. After instrument calibration was performed for Au and Gd estimation, the filtrate was analyzed by
ICP for quantitative estimation of Gd and Au.
MR Phantom Preparation for Relaxometry Measurements.
MRI measurements were recorded using a 4.7 T Bruker
Avance MR camier. Particle phantom were prepared for MR
relaxometry measurements by serially diluting a 10 mg/mL
stock solution of Gd-doped GSS nanoparticles with doubly
distilled H 2 0 and a 1% agarose solution (Ultra-Pure agarose,
Invitrogen, Carlsbad, Calif.) yielding a total concentration of
0.5% agarose. The resulting nanoparticle concentrations of 5,
2.5, 1.25, 0.625, and 0.3125 mg/mL were then injected into
100 µl capillary tubes (Curtin-Matheson Scientific, 181
Broomall, Pa.) and allowed to solidify on ice, thereby eliminating sedimentation during relaxometry measurements. The
comparison of MR response between Gd-doped GSS nanoparticles and silica nanoparticles (without any gold or Gd)
was performed similarly by diluting 10 mg/mL nanoparticles
in 1% agarose solution, confirming that the silica matrix alone
does not exhibit significant photo acoustic and MR contrast.
FIG. 3 and FIG. 4 demonstrate that silica does not exhibit
significant photo acoustic or MR contrast respectively. Control phantoms containing just 0.5% 187 and 1% agarose were
simultaneously imaged to determine effect of agarose on
relaxation times. Right before imaging, all samples were
placed together inside a water-filled FACS tube (BD Falcon,
Franklin Lakes, N.J.) to avoid susceptibility artifacts from the
surrounding air.
MR Relaxometry for Gd-Doped GSS Nanoparticles. All
relaxometry data was acquired at a 4.7 T horizontal bore
magnet with Paravision software (PV3.02; Bruker Medical).
For measuring T 1 relaxation times, axial spin-echo (SE) scan
sequences were obtained with TE=4.5 ms, matrix size) 128x
128, FOV=2.8 197x2.8 cm2 , spectral width=180 kHz, one
average, 1 mm slice thickness, and varying TR values of 11,
6, 3, 1.5, 0.75, 0.5, 0.25, 0.125, 0.075, 0.05, 0.025, and 0.015
s. For T 2 relaxation measurements, axial T 2 -weighted singleslice multiecho images were obtained with TR=l 1 s, TE=5
ms, llTE=5 ms (60 echoes), matrix size=128x128,
FOV=2.8x2.8 cm2 , spectral width=lOOkHz, two signal averages, and a 1 mm slice thickness. Analysis ofT 1 and T 2 values
was performed using Paravision 3 .02 software where T 1 and
T 2 maps were calculated assuming a monoexponential signal
decay and by using a nonlinear function, least-squares curve
fitting on the relationship between changes in mean signal
intensity within a region of interest (ROT) to TR and TE. T 1
and T2 relaxation times(s) for the Gd-doped GSS nanoparticles in 0.5% agarose were then derived by ROI measurements of the test samples converted into R 1 and R 2 relaxation

rates (1/T 1 2 (s- 1 )). Finally, R 1 2 values were plotted against
the concei:{tration of Gd on the nanoparticle and r 1 and r 2
(mM- 1 s- 1 ) relaxivities were obtained as the slope of the
resulting linear plot.
T 2 * relaxometry measurements were acquired by T2 *weighted FLASH gradient echo scan sequences. TRs were
kept constant at 500 ms with varying TEs of 4, 8, 12, 16, 20,
40, 60, and 100 ms, FOV=2.8x2.8 cm2 , matrix size=256x
256, two signal 219 averages, spectral width=60 kHz, and 1
mm slice thickness. Image J software (NIH) with an MR
analysis calculator plug-in was used to quantify T 2 *values by
stacking the individual FLASH sequences with varying TEs
and creating a T 2 *map. RO Is for each cell sample were then
drawn to contain the entire cross section of each of the
samples, and values were then plotted as R 2 * (or the inverse of
T 2 * (1/T 2 *, (s- 1 ))), against the concentration of Gd in the
sample (Excel, Microsoft Inc.). R 2 * relaxivity (mM- 1 s) was
later obtained as the slope of the resulting linear plot. Data are
presented as the mean±SD of measurements.
PAT Instrumentation. A mechanical scanning photoacoustic system with single acoustic transducer to collect the
acoustic signals was utilized. A pulsed Nd:YAG laser (Altos,
Bozeman, Mont.) working at 532 nm with 4 ns pulse duration,
10 Hz repetition rate and 3 60 ml maximum pulse power acted
as light source. The diameter of laser beam was expanded to
30 mm by a lens. An immersion acoustic transducer with 1
MHz nominal frequency (Valpey Fisher, Hopkinton, Mass.)
was driven by a motorized rotator to receive acoustic signals
and 360° for phantom cases at an interval of 3°, and thus a
total of 120 measurements were performed for one planar
scanning, respectively. The scamiing plane could be adjusted
along the z-axis by mounting the rotator and the transducer on
a platform driven by a linear stage. The acoustic transducer
was immersed into the water tank while the phantom was
placed at the center of the tank where it was illuminated by the
laser. The complex wave field signal was amplified by a
pulser/receiver (GE Panametrics, Waltham, Mass.) and then
was acquired by a high-speed PCI data acquisition board. PAT
images were reconstructed by a reconstruction algorithm that
is based on the finite element solution to the photoacoustic
wave equation in the frequency domain, which can provide
stable inverse solutions. Phantoms for imaging were constructed using intralipid, India ink, distilled water, and 2%
agar powder as described above. The diameters of all phantoms used in this study were 25 mm. The absorption and
reduced scattering coefficients (optical properties) of these
phantoms were 0.007 and 0.5 255 mm- 1 , respectively. Nanoparticles were embedded in the phantom 256 at a depth of 2
mm for imaging.
Macrophage Labeling and Phantom Preparation for MRI
and PAT. Mouse monocyte/macrophage 1774 cells were
defrosted, resuspended in DMEM complete, consisting of
Dulbecco's modified agle's medium (DMEM) (GIBCO,
Grand Island, N.Y.) supplemented with 10% fetal bovine
serum (Summit Biotechnology, Ft. Collins, Colo.), 1%
glutamax (GIBCO), 1% penicillin/streptomycin (GIBCO),
and incubated at a density of 5xl05 cells/mL in 100 mm
culture dishes at 37° C. and 5% C02. Media was replaced 24
h after plating, and the cells were allowed to attach and grow
to confluency (usually within 2-3 days). Old media was
replaced with fresh before the cells were harvested and
washed twice by spinning them down at 1100 rpm for 5 min
using a Sorvall RT7 plus ultracentrifuge and resuspending in
fresh DMEM complete media. Cells were subsequently
replaced at a density of 2x 105 and again allowed to attach and
grow to confluency. Cells were passaged for 3-4 times before
the start of the labeling experiment. During labeling, 1xl0 6
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freshly split 1774 cells/mL DMEM complete were incubated
overnight with 100 µg/mL of Gd-doped GSS nanoparticles in
a six-well tissue culture dish. The next day label-containing
media was aspirated off and replaced by fresh media before
labeled and unlabeled control cells were scraped up, washed
twice in ice-cold Dulbecco's phosphate-buffered saline
(DPBS) (GIBCO, Grand Island, N.Y.), counted, and resuspended at a density of 3.33xl07 cells/mL each in DPBS
(2xl 0 6 cells in 60 µL DPBS). Cells were kept on ice until the
time of imaging when 20 µl of cell suspension was then
injected in the phantom. The same phantom was used for MRI
and PAT experiments in succession.
MRI Measurements on 177 4 Cells Labeled with Gd-Doped
GSS Nanoparticles. The sample phantom containing GSSlabeled 1774 and control cells was placed inside a solenoid
coil and imaged at 4.7 T magnetic field strength with Paravision software (PV3.02; 288 Bruker Medical). T 1 - and
T 2 -weighted SE scan sequences were used to detect Gd on the
nanoparticles inside the cells. For generating T 1 -weighted
images a multislice multiecho (MSME) pulse sequence was
used with TR=500 ms, TE=5 ms, matrix size=256x256,
FOV=3x3 cm2 , spectral width=! 00 kHz, two signal averages,
and a 1 mm slice thickness. T 2 -weighted images was acquired
either by using a MSME pulse sequence with TR=500 ms,
TE=lOO ms, matrix size 256x256, FOY 3x3 cm 2 , spectral
width=lOOkHz, two signal averages, anda 1 mm slice thickness or by using a rapid acquisition with relaxation enhancement (RARE) pulse sequence with TR= 1000 ms, TE= 12 ms,
matrix size=256x256, FOV=3x3 cm2 , spectral width=60
kHz, four signal averages, RARE factor=8, and a 1 mm slice
thickness.
In one embodiments of the invention, gold-silica hybrid
material termed gold speckled silica (GSS) nanoparticles are
provided. These MRI-PAT-active multimodal nanoparticles
have a surface layer composed of discontinuous, irregular
gold nanodomains of varying crystallinity that are incorporated within the pores and on the exterior of the supporting
silica matrix. The multitude of dielectric-metal interfaces
created by this method gives rise to unique photothermal
properties that enable the use of these materials as contrast
agents in PAT. The multimodal GSS nanoparticles possess
high relaxivity for MRI and at the same time produce a strong
PAT contrast.
In one embodiment, the GSS nanoparticles are formed by
first forming Gd-doped silica nanoparticles by co-condensation of TEOS and a silane reagent that strongly chelates
polyvalent metal ions (TSPETE) in the water core of the
TX-100/n-hexanol/water W/0 microemulsion. Incorporation
of chloroauric acid followed by its reduction was then carried
out within the surface layer of the silica nanoparticles. By
manipulating W 0 of the microemulsions and the reactant concentrations, we were able to tune Gd-doped GSS nanoparticle
size from less than 50 to 200 nm. FIGS. S(a) and S(b) show
representative TEM micrographs for two different samples
prepared at W 0 10 and 14, depicting mean particle size of
about 100 (±10) and 55 (±5) nm, respectively. GSS nanoparticles up to 200 nm and larger were synthesized at W 0 5 using
the same microemulsion system. FIG. 6 shows large sized
(>200 nm) GSS nanoparticles prepared in the Tx-100/cyclohexane/water system at W 0 =5, following the conditions as
described above.
The particle sizes were confirmed using DLS and disk
centrifuge techniques. In one embodiment of the invention,
by incubating Gd-doped silica nanoparticle within the aqueous core of the microemulsion with chloroauric acid, gold
ions permeate further into the mesoporous silica matrix.
Upon reduction, a unique gold-speckled surface results due to

the deposition of the gold nanodomains. The gold nanodomains are discontinuous, randomly deposited, sometimes
templated, and irregular gold nanoclusters can form within
and on the surface of the silica core. High-resolution TEM
(HR-TEM) micrographs of about 100 nm Gd-doped. GSS
nanoparticles (prepared at WO=lO) demonstrate speckled
surface deposits of gold, as seen in areas of darker contrast on
the silica surface in FIG. 7(a) and as areas oflighter contrast
in the dark-field TEM shown in FIG. 7(b). Note that Gd
doping also contributes to the background as a darker and
lighter haze in FIG. 7(a) and FIG. 7(b), respectively. The
HRTEM micrograph of FIG. 8 shows scattered deposition of
gold nanoparticles ranging from less than 1 to 5 nm, with
varying crystallinity, on the silica surface. These random and
irregular clustered deposits include templated deposits. The
mesopores make this class of particles distinct and accounts
for their unique optical properties such as efficient photothermal properties. Since these particles were also doped with Gd
ions, a paramagnetic species that affects the longitudinal
relaxation rate of water, they provided MRI contrast.
The elemental composition of the Gd-doped GSS nanoparticles particles was determined using EDS and lCP techniques. An EDS spectrum is shown in FIG. 9 with spectral
counts corresponding to Si, 0, Au, Gd, and the overall spectrum for the nanoparticle, respectively. The elemental composition as determined by ICP gave average number of atoms
of Au and Gd to be about 426 200 and about 34 000 per
nanoparticle, respectively. Theoretical calculations showed
that about 72 times more number of gold atoms would be
present in a single gold nanoparticle of similar dimension.
The Gd-doped GSS nanoparticles generated MR contrast
on both T 1 and T 2 proton relaxation time weighted sequences,
as are shown in FIG. lO(a) and FIG. lO(b). Quantitatively,
MR contrast is evaluated by the relaxivity of the nanoparticle.
The relaxivity (R,, i=l, 2) is defined as the gradient of the
linear plot ofrelaxation rates (l!T,, i=l, 2) versus Gd concentration [Gd], i.e., l/T,=l/T 0 +R,[Gd], where Ti is the relaxation time for a contrast agent solution concentration [Gd]
and T 0 is the relaxation time in the absence of a contrast agent.
From the data shown in FIG. 11, the relaxivities R 1 , R 2 , and
R 2 * are determined to be 13, 110, and 173mM- 1 s- 1 ,respectively. Gd-GSS exhibit much higher relaxivity values than
commercially available contrast agents under the same magnetic strength of 4.7 T. In MRI, it is well-established that the
Gd-generated MR contrast relies on the relaxation process of
the water molecules in association with the Gd ion and those
exchanged in the surrounding environment. For an efficient
relaxation process, rapid water exchange between bound (or
inner coordination water) with the bulk water and slow tumbling play an important role. The Gd-doped GSS nanoparticles address both these factors. First, the presence of the
discontinuous GSS surface allows sufficient bulk water
exchange with the Gd ions enabling MR tracking ability. In
comparison, a continuous gold shell over the silica core could
limit the extent of water exchange inhibiting T 1 contrast.
Second, tumbling rates are another important factor for producing an effective MRI contrast is also reduced in the Gd
doped GSS particles through the rigid binding of Gd to the
nanoparticle surface. Because the tumbling rates are mass
dependent, nanoparticles are much slower than free Gd chelates and thus produce an enhanced relaxation. One of the
major limitations of current molecular chelates used as MR
contrast agent is their low sensitivity; this requires the use of
higher dosages and results in poor targetability. Both of these
problems are addressed by embodiments of the invention.
Approximately, 34 000 ions of Gd are captured per nanoparticle with an average size of 100 nm, which is higher than the
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number of Gd ions previously reported in other nanoparticles
such as synthetic polymers (6-70 ions) and in dendrimers
(between 5 and 1331 ions, strongly dependent on particle
size) and comparable to perfluorocarbon nanoparticles (90
000 Gd ions in 250 nm diameter particle). The ability of
Gd-GSS nanoparticles to generate photoacoustic contrast
was confirmed by placing the particles in an agar phantom
containing India ink and intralipid to simulate tissue-like
absorption and scattering. FIG. 12 shows the comparison of
PAT contrast from GSS nanoparticles and compares it to that
of similar size and concentration of gold nanoparticles. The
dark red region in the area ofthenanoparticles, with respect to
the blue background, demonstrates that a strong PAT contrast
is observed from the particles. As shown in FIG. 12, the GSS
nanoparticles generated a strongerphotoacoustic signal when
compared the GSS nanoparticles, in spite of the presence of
-72-fold less gold atoms, demonstrates them as a better PAT
contrast agent. Control experiments were also performed
using silica nanoparticles (without Au or Gd) which illustrated that the bare silica nanoparticles do not have a significant PAT contrast. Because the PAT originates from the optical absorption of the illuminating laser wavelength, the GSS
particles also hold therapeutic potential for the thermal ablation of tumors. Hence, the particles described here hold both
multimodal imaging as well as therapeutic capabilities. To
evaluate the bimodal character of the GSS nanoparticles,
simultaneous MR and photoacoustic evaluation was carried
out. To achieve this, the GSS particles were placed in tissuelike phantom. The phantom was imaged for PAT and MR in
succession, and the results are shown in FIGS. 13(a) and (b),
respectively. An increase in the MR and PAT signal intensity
is observed with increasing particulate concentration. In vitro
studies were carried out with the GSS nanoparticles to assess
the functional ability of the particles in the cellular environment. The uptake of the GSS nanoparticles by 1774 macrophages was carried out as described above. The cells were
placed in tissue-like phantom and imaged by PAT and MRI in
succession. FIG. 14 shows the phantom design with the
sample placement and the MR and PAT images obtained with
the same phantom. It is observed that the cells labeled with the
GSS nanoparticles produce a strong PAT contrast as compared to the background. The MRI image of the same phantom shows the ability to generate the T 1 and T 2 contrast. The
in vitro experiments demonstrated the capability of the GSS
nanoparticles to generate an efficient PAT and MR contrast in
contrast in living cells, showing potential use of GSS nanoparticles as in vivo cell tracker.
Multimodal nanoparticles with silica core according to an
embodiment of the invention can be made fluorescent by
coupling Fluorescein isothiocyanate (FITC) can be prepared
in the manner described above for the GSS particles. Alanthanide metal was attached to the surface of the core by
co-condensing a silane ligand on the silica surface. The particle surface was then coated with gold within the water core
of the microemulsion. This led to the gold speckled surface
coated multimodal nanoparticles shown in FIGS. 15(a) and
15(b) as SEM and TEM images, respectively, of the multimodal nanoparticles. Using Dynamic Light Scattering, the
size of the multimodal nanoparticles was determined to be
about 50 nm to about 100 nm.
The multimodal nanoparticles generated contrast in MR
images, where glass micropipettes (250 µL in volume) were
filled with about 200 µL of serial dilutions of multimodal
particles and placed in a single-tuned solenoid coil (200
MHz) with an inner diameter of 1 cm, and data were recorded
at room temperature using a 4.7 T (200 MHz) Bruker Avance
MR scanner.Tu T 2 , and T 2 * relaxivities for the particles were

determined from the slope of the relaxation graphs obtained
by serial dilutions of the sample normalized to Gd. The T 1
contrast generated from the serial dilutions of the nanoparticles at 5 mg/mL, 2.5 mg/mL, 1.25 mg/mL, 0.625 mg/mL,
0.3125 mg/mL suspended in 0.5% agarosewitha TR ofl 1000
ms and TE of 4.5 ms was clearly enhanced relative to 1% and
0.5% agarose solution controls.
PAT contrast from the multimodal nanoparticles was determined where pulsed light with incident fluence ofl 0 mJ/cm2 ,
well below the safety standard from a Nd: YAG laser (wavelength: 532 nm, pulse duration: 4 ns) was coupled into the
phantom via an optical subsystem and generated acoustic
pressure wave. A wide-bandwidth, 1 MHz transducer was
used to receive the acoustic signals. The transducer and the
phantom were immersed in a water tank. A rotary stage
rotated the receiver relative to the center of the tank. One set
of data was taken at 120 positions when the receiver was
scanned circularly over 360°. The PAT picture was generated
by processing the data collected using standard algorithms.
The ability to generate x-ray contrast by the multimodal
particles was demonstrated by suspending about 20 mg/ml of
nanoparticles in nanopure water, using nanopure water as
control. FIG. 16 shows the strong x-ray contrast generated
from the iron doped multimodal nanoparticles.
In vivo testing using the exemplary multimodal nanoparticles for MRI and PAT was then performed. Two (2) million
1774 cells labeled with the multimodal nanoparticles were
injected into the right leg of the mouse while unlabeled cells
were injected into the left leg. The animal was MR imaged on
4.7 T MRI scanner immediately following injection. The in
vivo MR images shown in FIG. 17 demonstrate the ability of
the particles to generate sufficient MR contrast in live animals.
An MCF7 tumor was grown in the mouse abdomen. PAT
images were taken before and after the injection of multimodal nanoparticles injected in the MCF7 tumor. FIG. lS(a) and
FIG. 18(b) show the PAT images obtained under similar
experimental conditions for a tumor before and after injection
with the multimodal nanoparticles. It is shown clearly that the
particles can be used to image the tumor, in vivo conditions.
GSS nanoparticles doped with FITC dye were prepared in
the microemulsion in the manner described above. GSS nanoparticles were pegylated by reacting with Peg-thiol using
standard protocols. 100 µl (particle concentration 10 mg/mL)
pegylated nanoparticles were injected in the tail vein of the
animal model (breast cancer). The tumor region in the animal
was monitored by PAT before and after the injection of nanoparticles at 3 and 5 hour interval. The nanoparticles injected
into the animal model were passively targeted to the tumor
site by the well known Enhanced permeability and retention
(EPR) effect.
Results from a PAT experiment and ex-vivo fluorescence
studies are shown in FIG. 19. FIG. 19(a) shows a representative PAT image from subtraction ofinitial PAT image (prior to
injection of nanoparticles) from the PAT image obtained 3
hour post injection. The deep red regions (appearing as a
plurality of dark regions within a white region of the image)
result from the localization of the GSS particles around the
tumor. To confirm the findings from PAT imaging, tumor
sections from the animal model were checked for fluorescence after sacrificing the animal. FIG. 19(b) shows the fluorescence image of the tumor tissue section. The green fluorescence (white in the grayscale reproduction of the image)
emanates from the presence of fluorescent-GSS nanoparticles
(FITC) in the tumor vasculature and the blue fluorescence
(gray in the grayscale reproduction of the image) is seen from
the nuclear stain DAPI. Hence this confirms that GSS nano-
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particles can be tracked non-invasively using PAT in vivo and
can be confirmed by a second mode (fluorescent) in the multimodal nanoparticles. The GSS nanoparticles have an
absorption maximum at about 530 nm and, in general,
strongly absorbs in the region of 450 to 850 nm. This absorption is remarkably different from the starting materials i.e.
silica and gold chloride. The light absorbing character of GSS
nanoparticles in the visible to Near Infrared (NIR) wavelength range makes the particles generate heat as a result of
such absorption making them useful for therapeutic hyperthermia applications. FIG. 20 shows the rise in temperature of
solution containing GSS nanoparticles (10 mg/mL) when
illuminated with 785 nm NIR laser. The laser output was
maintained at 350 mA during the experiment. GSS nanoparticles showed a rise of -15° C. in 5 minutes on continuous
illumination with NIR laser as compared to about 1° C. rise
observed with nano pure water. For hyperthermia, an increase
of about 8-10° C. over the normal physiological temperature
is known to cause disruption of the cellular metabolism leading to eventual death. From the above results it is apparent that
GSS nanoparticles are capable of sufficiently elevating the
temperature to kill tumor cells.
Lung A549 cancer cells were dosed with GSS nanoparticles in various combinations of time and concentration; 18
hrs incubation for 5 and 10 µg/ml; and 24 hrs incubation for
20 µg/ml. Prior to illuminating the cells with a 785 nm laser
the media was removed and the cells were rinsed with HBSS
(Hanks Buffered Saline Solution) twice and fresh growth
media was added. FIG. 21 shows the representative images of
cells before and after exposure to laser. From FIG. 2l(c) and
FIG. 21(d), before and after irradiation, it is clearly obvious
thatA549 cells labeled with GSS nanoparticles undergo thermally induced cell death when exposed to laser light. The
process of laser illumination on GSS labeled cells and the
effect of increase in temperature on cellular components has
been studied by Raman spectroscopy. The overall process of
cell death has been found to be necrotic. In this study a Raman
technique as a tool to investigate effect of rise in temperature
on the cell components.
In another experiment the effectiveness of the particles to
cause possible collateral damage on surrounding cells (those
not exposed to laser) was studied. The labeled cells were
illuminated with Laser of (20 by 40 micron spot size) at an
estimated the speed to 2.5 mm/s. After the laser scanning was
finished, 200 µl of 0.4% Trypan Blue solution in phosphate
buffer was added to the cells. The plate was incubated for 15
min in order for the Trypan Blue to selectively penetrate the
membrane and color the dead cells. Images were taken with
Olympus BX60 with an attached SPOT Insight Digital Camera, as shown in FIG. 22. The cells labeled with GSS nano-

particles falling in the path of the laser are killed selectively,
as shown as a dark vertical line at the center of FIG. 22(a)
which is magnified in FIG. 22(b).
The ability to generate heat using with NIR laser allows
targeting deep tumors due to higher penetration in this region.
To demonstrate the feasibility of using GSS nanoparticle for
tumor hyperthermia, GSS nanoparticles were injected
directly into the tumor of animal model. The tumor region
was then illuminated with 785 nm laser (0.350 mA output) for
duration of 5 minutes. The effect on the tumor was checked by
performing the histological analysis of the tumor after sacrificing the mice. FIG. 23 shows the image of the tumor post
ablation experiment. It is evident from the figure that the GSS
nanoparticles caused significant damage to the tumor tissue
from theheat generated due to exposure to NIRlight. FIG. 24
shows the Hand Estain of the tumor section.
It should be understood that the examples and embodiments described herein are for illustrative purposes only and
that various modifications or changes in light thereof will be
suggested to persons skilled in the art and are to be included
within the spirit and purview of this application.
We claim:
1. A multimodal nanoparticle comprising:
a dielectric core comprising at least one oxide;
a metal deposition on said core, wherein said metal deposition is speckled; and
a plurality of at least one moiety that exhibits fluorescence,
magnetic or paramagnetic properties, or any combination thereof, wherein saidmultimodal nanoparticle comprises a contrast agent for photo acoustic tomography
(PAT) imaging and x-ray imaging, and at least one of
luminescence imaging moiety and/or magnetic resonance (MR) imaging moiety, and wherein said metal
deposition and said dielectric core have an interface with
interpenetrated gradient.
2. The nanoparticle of claim 1, wherein said luminescence
imaging moiety comprises at least one of a dye, a quantum
dot, and a phosphor.
3. The nanoparticle of claim 1, wherein the MR imaging
moiety comprises at least one lanthanide or transition metal.
4. The nanoparticle of claim 1, wherein the oxide comprises silicon dioxide.
5. The nanoparticle of claim 1, wherein the metal deposition comprises gold.
6. The nanoparticle of claim 1, wherein saidnanoparticle is
further surface modified with at least one biomolecule or
surface functional group for specific targeting of a tumor cell
or other biological tissue.
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It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Specifications
Column l,
Lines 11-15, "by reference in their entireties, including all figures, tables or drawings." should read
--by reference in their entireties, including all figures, tables or drawings.
This invention was made with government support under contract number EEC0506560
awarded by the National Science Foundation. The government has certain rights in the
invention.
BACKGROUND OF THE INVENTION--.
Column l,
Line 65, "In an embodiments" should read --In an embodiment--.
Column2,
Line 31, "and x-rays" should read--and x-ray--.
Column 3,
Line 20, "Where The GSS" should read --where the GSS--.
Column4,
Line 13, "Fig. l 7B" should read --Fig. l 7B is--.
Line 15, "Fig. l 7C" should read --Fig. l 7C is--.
Line 17, "Fig. l 7C" should read --Fig. l 7D is--.
Line 59, "agents, an x-ray contrasting" should read --agents, x-ray contrasting--.
Column 6,
Line 38, "for 24 hour" should read --for 24 hours--.

Signed and Sealed this
Eleventh Day of June, 2013

Teresa Stanek Rea
Acting Director of the United States Patent and Trademark Office

CERTIFICATE OF CORRECTION (continued)
U.S. Pat. No. 8,361,437 B2
Column 7,
Line 24, "MR canner" should read --MR scanner--.
Line 51, "maxtrix size) 128" should read --matrix size 128--.
Column 8,
Line 53, "modified agle's medium" should read --modified eagle medium--.
Column 10,
Line 22, "EDS and JCP" should read --EDS and ICP--.
Column 12,
Line 48, "at 3 and 5" should read --at 1, 3 and 5--.
Column 13,
Line 38, "technique as a tool to investigate" should read --technique was used as a tool to
investigate--.
Line 44, "estimated the speed to" should read --estimated speed of--.
Column 14,
Line 4, "using with NIR laser" should read --using an NIR laser--.
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